217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma

Multicentre Study ◽

Phase I ◽

Open Label ◽

Anti Tumour Activity ◽

Metastatic Hepatocellular Carcinoma ◽

A phase II open-label, multicentre study to assess the anti-tumour activity of afatinib in patients with activating epidermal growth factor receptor mutation (EGFRm) from circulating tumour DNA (CtDNA)

Annals of Oncology ◽

10.1093/annonc/mdz260.061 ◽

2019 ◽

Vol 30 ◽

pp. v632

Author(s):

Y.-C. Kim ◽

C.-K. Park ◽

I.-J. Oh ◽

S.Y. Lee ◽

J.C. Lee ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Multicentre Study ◽

Growth Factor Receptor ◽

Open Label ◽

Anti Tumour Activity ◽

Epidermal Growth ◽

Circulating Tumour Dna ◽

A phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma

Annals of Oncology ◽

10.1093/annonc/mdy282.080 ◽

2018 ◽

Vol 29 ◽

pp. viii234-viii235 ◽

Cited By ~ 1

Author(s):

A.-L. Cheng ◽

C.-J. Yen ◽

T. Okusaka ◽

M. Ikeda ◽

C.-H. Hsu ◽

...

Keyword(s):

Metastatic Hepatocellular Carcinoma

Monoclonal Antibody ◽

Phase I ◽

Dose Escalation ◽

Locally Advanced ◽

Open Label ◽

Dose Escalation Study ◽

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study

Annals of Oncology ◽

10.1093/annonc/mdy487.004 ◽

2018 ◽

Vol 29 ◽

pp. x26 ◽

Cited By ~ 1

Author(s):

A.R. He ◽

G.J. Weiss ◽

G. Falchook ◽

N.S. Yee ◽

M. Gil-Martin ◽

...

Keyword(s):

Phase I ◽

Phase I Study ◽

Metastatic Hepatocellular Carcinoma ◽

Expansion Cohort

A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma

British Journal of Cancer ◽

10.1038/s41416-018-0051-8 ◽

2018 ◽

Vol 118 (9) ◽

pp. 1162-1168 ◽

Cited By ~ 5

Author(s):

D. H. Palmer ◽

Y. T. Ma ◽

M. Peck-Radosavljevic ◽

P. Ross ◽

J. Graham ◽

...

Keyword(s):

Phase I ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Hepatocellular Carcinoma ◽

Open Label ◽

Open Label Phase

An open-label, multi-center, phase I/II, dose escalation study of IV TKM-080301 in subjects with advanced hepatocellular carcinoma

European Journal of Cancer ◽

10.1016/s0959-8049(16)32646-6 ◽

2016 ◽

Vol 69 ◽

pp. S22 ◽

Cited By ~ 1

Author(s):

G.K. Abou-Alfa ◽

J.H. Yoon ◽

M. Modiano ◽

B.Y. Ryoo ◽

T. Yau ◽

...

Keyword(s):

Phase I ◽

Dose Escalation ◽

Advanced Hepatocellular Carcinoma ◽

Open Label ◽

Dose Escalation Study

Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study

Investigational New Drugs ◽

10.1007/s10637-014-0101-x ◽

2014 ◽

Vol 32 (5) ◽

pp. 995-1004 ◽

Cited By ~ 30

Author(s):

Yohann Loriot ◽

Karim Fizazi ◽

Robert J. Jones ◽

Jan Van den Brande ◽

Rhoda L. Molife ◽

...

Keyword(s):

Prostate Cancer ◽

Phase I ◽

Castration Resistant Prostate Cancer ◽

Biosynthesis Inhibitor ◽

Castration Resistant ◽

Anti Tumour Activity ◽

949P Thermal ablation plus toripalimab in patients with advanced hepatocellular carcinoma: Phase I results from a multicenter, open-label, controlled phase I/II trial (IR11330)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.169 ◽

2021 ◽

Vol 32 ◽

pp. S826

Author(s):

L. Shi ◽

C. Zhou ◽

X. Long ◽

H. Li ◽

C. Chen ◽

...

Keyword(s):

Phase I ◽

Thermal Ablation ◽

Advanced Hepatocellular Carcinoma ◽

Open Label

Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort in a phase I study

Annals of Oncology ◽

10.1093/annonc/mdy288.024 ◽

2018 ◽

Vol 29 ◽

pp. viii410 ◽

Cited By ~ 3

Author(s):

M.J. Pishvaian ◽

G.J. Weiss ◽

G.S. Falchook ◽

N. Yee ◽

M. Gil-Martin ◽

...

Keyword(s):

Phase I ◽

Phase I Study ◽

Metastatic Hepatocellular Carcinoma ◽

Expansion Cohort

787 EFFECTS OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS OF BRIVANIB IN A PHASE I, OPEN-LABEL, MULTIDOSE STUDY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AND OTHER SOLID TUMORS

Journal of Hepatology ◽

10.1016/s0168-8278(09)60789-3 ◽

2009 ◽

Vol 50 ◽

pp. S288 ◽

Cited By ~ 2

Author(s):

A. El-Khoueiry ◽

H.J. Lenz ◽

J. Posey ◽

T. Wood ◽

B. Fischer ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Hepatic Impairment ◽

Open Label

In vivo anti-tumour activity of corilagin on Hep3B hepatocellular carcinoma

Phytomedicine ◽

10.1016/j.phymed.2010.09.001 ◽

2010 ◽

Vol 18 (1) ◽

pp. 11-15 ◽

Cited By ~ 41

Author(s):

Desmond Kwok-Po Hau ◽

Guo-Yuan Zhu ◽

Alexander Kai-Man Leung ◽

Raymond Siu-Ming Wong ◽

Gregory Yin-Ming Cheng ◽

...

Keyword(s):

Anti Tumour Activity ◽